Hepatitis C Drugs Market Segmentation:
By Drug Class (Revenue, USD Bn, 2021 - 2033)
- NS3/4A Protease Inhibitors
- NS5A Inhibitors
- NS5B Polymerase Inhibitors
- Combination Drugs
- Others
By Route of Administration (Revenue, USD Bn, 2021 - 2033)
- Oral Drugs
- Intravenous
- Others
By Distribution Channel (Revenue, USD Bn, 2021 - 2033)
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
Regional Insights (Revenue, USD Bn, 2021 - 2033)
- North America
- U.S.
- Canada
- Latin America
- Brazil
- Argentina
- Mexico
- Rest of Latin America
- Europe
- Germany
- U.K.
- Spain
- France
- Italy
- Russia
- Rest of Europe
- Asia Pacific
- China
- India
- Japan
- Australia
- South Korea
- ASEAN
- Rest of Asia Pacific
- Middle East
- GCC Countries
- Israel
- Rest of Middle East
- Africa
- South Africa
- North Africa
- Central Africa
- North America